Glenmark receives US FDA approval for Icatibant Injection
Glenmark receives US FDA approval for Icatibant Injection
25 May 2021 | News The injection will be manufactured in their North American manufacturing facility based in Monroe, North Carolina
Glenmark Pharmaceuticals (Glenmark) has received final approval by the United States Food & Drug Administration (US FDA) for Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe, the generic version of Firazyr 1 Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe, of Shire Human Genetic Therapies. This marks Glenmark s first synthetic decapeptide injectable approval and will be manufactured in their North American manufacturing facility based in Monroe, North Carolina.
Glenmark Pharma launches nasal spray Ryaltris in India
SECTIONS
Last Updated: May 03, 2021, 11:25 AM IST
Share
Synopsis
Glenmark being one of the leaders in respiratory segment, has been the first to launch the branded generic version at an affordable cost for the treatment of allergic rhinitis in India.
Agencies
Glenmark Pharma on Monday announced of launch its nasal spray Ryaltris, used for treatment of moderate to severe allergic rhinitis, in India.
Glenmark being one of the leaders in respiratory segment, has been the first to launch the branded generic version at an affordable cost for the treatment of allergic rhinitis in India. This will provide patients a far more convenient, cost effective treatment option in the country, Glenmark said in a regulatory filing.
Glenmark launches nasal spray in India for treating allergic rhinitis
Glenmark launches nasal spray in India for treating allergic rhinitis
03 May 2021 | News Glenmark becomes the first company in the world to launch Ryaltris®-AZ as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg
image credit- shutterstock
Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company, announced the launch of Ryaltris®-AZ Nasal Spray for the treatment of moderate to severe allergic rhinitis, in India. Glenmark being one of the leaders in respiratory segment, has been the first to launch the branded generic version at an affordable cost for the treatment of allergic rhinitis in India.
Mumbai (Maharashtra) [India], May 3 (ANI/PRNewswire): Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company, announced the launch of Ryaltris®-AZ Nasal Spray for the treatment of moderate to severe allergic rhinitis, in India.
Glenmark being one of the leaders in respiratory segment, has been the first to launch the branded generic version at an affordable cost for the treatment of allergic rhinitis in India. This will provide patients a far more convenient, cost-effective treatment option in the country.
Glenmark is the first company in the world to launch Ryaltris®-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg.